News
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza Group AG signs agreement to acquire Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion. Acquisition aims to expand large-scale biologics manufacturing capacity, enhance capabilities, and update sales growth guidance -
-
COMMUNIQUÉ DE PRESSE
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Lonza Group AG reports solid 2023 performance with 10.9% CER sales growth and 29.8% CORE EBITDA margin. Proposed 14% dividend increase and continued growth investment with 2023 CAPEX at 25% of sales.